The global anticoagulant reversal drugs market size is expected to reach USD 2.20 billion by 2028 according to a new study by Polaris Market Research. The report “Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Most common bleeding disorders include hemophilia A and B, and Von Willebrand disease (VWD). As per the data published by the National Hemophilia Foundation (NHF), in the U.S alone, more than 30,000 to 33,000 million people are suffering from hemophilia, and around 60% were accounted for the lethal form.
VWD is one of the common forms affecting one in every 100 people. Such bleeding disorders affect blood clotting and are expected to result in excessive bleeding both inside and outside the body. This extensive bleeding can cause death in individuals and necessitates the use of anticoagulant reveral drugs.
Download sample: https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-sample
Certain surgeries such as atrial fibrillation, ischemic stroke, pulmonary embolism, heart-related ailments, and deep vein thrombosis require anticoagulants. As per the estimates of the CDC, over 2% of the people aged below 65 years suffer from atrial fibrillation, while 9% aged above 65 years usually develop this condition. It is also predicted that by 2030 around 12.1 million people will develop such conditions. It is also being estimated that around 60,000-100,000 U.S. individuals suffer die from deep vein thrombosis.
North America market accounted for the highest revenue share in 2020 and is expected to maintain its dominance over the forecast period. This can be attributed to the easy availability of the anticoagulant reversal drugs, high consumer expenditure in the healthcare sector, and favorable healthcare-related policies for consumers in U.S. and Canada.
However, Asia Pacific anticoagulant reversal drugs industry is projected to witness the fastest market growth rate over the study period. This growth is due to growing cases of bleeding disorders in the huge population in emerging economies.
Moreover, increased medical attention and awareness of the disease among individuals also supporting the region’s market growth. Increased attention of the key players in the market in the booming region also complemented its market growth for anticoagulant reversal drugs.
Market participants such Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind. Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy’s Laboratories, SG Pharma Pvt Ltd., and Fresenius Kabi AG.
Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-discount-pricing
Polaris Market Research has segmented the anticoagulant reversal drugs market report on the basis of product, distribution channel and region:
Anticoagulant Reversal Drugs, Product Outlook (Revenue – USD Million, 2016 – 2028)
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Idarucizumab
- Protamine
- Others
Anticoagulant Reversal Drugs, Distribution Channel Outlook (Revenue – USD Million, 2016 – 2028)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Anticoagulant Reversal Drugs, by Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Netherlands
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Central & South America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Buy Now: https://www.polarismarketresearch.com/checkouts/8361
The global anticoagulant reversal drugs market size is expected to reach USD 2.20 billion by 2028 according to a new study by Polaris Market Research.
The report “Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.Moreover, increased medical attention and awareness of the disease among individuals also supporting the region’s market growth.
Increased attention of the key players in the market in the booming region also complemented its market growth for anticoagulant reversal drugs.
Market participants such Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind.
Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy’s Laboratories, SG Pharma Pvt Ltd., and Fresenius Kabi AG.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-sample The study objectives are:To analyze and research the global Anticoagulant Reversal Drugs Market capacity, production, value, consumption, status and forecast;To focus on the key Anticoagulant Reversal Drugs Market manufacturers and study the capacity, production, value, market share and development plans in next few years.To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.To define, describe and forecast the market by type, application and region.To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.To identify significant trends and factors driving or inhibiting the market growth.To analyze the opportunities in the market for stakeholders by identifying the high growth segments.To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Anticoagulant Reversal Drugs, by Regional Outlook (Revenue – USD Million, 2016 – 2028)North AmericaS.CanadaEuropeFranceGermanyUKItalySpainNetherlandsAustriaAsia PacificChinaIndiaJapanMalaysiaSouth KoreaIndonesiaCentral & South AmericaMexicoBrazilArgentinaMiddle East & AfricaUAESaudi ArabiaIsraelSouth AfricaGet Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-discount-pricingAbout Polaris Market ResearchPolaris Market Research is a Middle East market research and consulting company.
The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.Contact Us:Polaris Market ResearchPhone: 1–646–568–9980Email: [email protected]: www.polarismarketresearch.com
COVID-19 Impact Analysis on Anticoagulant Reversal Drugs Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2019-2027.
The report encompasses data regarding market share and recent developments by key players.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Anticoagulant Reversal Drugs include Portola Pharmaceuticals, CSL Behring, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Pfizer, Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Octapharma AG, SGPharma Pvt.
Ltd., and Alps Pharmaceutical Ind.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Anticoagulant Reversal Drugs Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/anticoagulant-reversal-drugs-market/download-sampleMarket SegmentationThe broad Anticoagulant Reversal Drugs has been sub-grouped into the Product Type, Distribution Channel and Region.
Moreover, this market report also covers regional and country market in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the renal anemia treatment market include Amgen Inc., ViforPharma Management Ltd., Hoffmann-La Roche Ltd., Pfizer Inc., Sandoz International GmbH (Novartis AG), Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Rockwell Medical, Akebia Therapeutics.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Renal Anemia Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/renal-anemia-treatment-market/download-sampleMarket DynamicsChanging lifestyles and unhealthy eating habits are the major drivers for the growth of the renal anaemia treatment market.
increasing global population and the rising number of chronic diseases like kidney failure are some of the factors which can propel the growth of this market.
The COVID-19 pandemic has no direct relationship with renal anaemia but people with chronic conditions have higher chances of contracting one due to the change in lifestyle introduced by the lockdown.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis.
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
The Global Anticoagulant Reversal Drugs Market 2020 explores the implications of a wide variety of factors influencing market drivers and growth.
In addition, this study reviews the global Anticoagulant Reversal Drugs Market wholesalers, channels of bargains, challenges, opportunities, boosters, potential examples, rate of change, market share, and status.A detailed analysis into the market position of Anticoagulant Reversal Drugs market competitiveness, benefits and downside of enterprise stock, industry growth patterns in the studied market, regional industrial layout attributes and economic policies, industry News and Strategies has been included.Get sample report@ https://www.kdmarketinsights.com/sample/6463The report covers segmentation analysis of Anticoagulant Reversal Drugs Market for better understanding and provides in-depth information on market outlook.
Important segments have been developed and analyzed to facilitate sound business decisions.
Each segment and its sub-segments are evaluated on the basis of their growth prospects, market share and CAGR.
This section reveals high-growth market segments and understands how the market will expand over the forecast period.Based on region, the global Anticoagulant Reversal Drugs market is segmented into:North America (U.S. & Canada)Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe)Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)Latin America (Brazil, Mexico, and Rest of Latin America)Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa)Get Complete Research Report with TOC@ https://www.kdmarketinsights.com/product/6463/anticoagulant-reversal-drugs-marketRelevant points Highlighted:The report includes an overall business forecast that aims to gain valuable insights into the global Anticoagulant Reversal Drugs market.The main segments have been further classified into sub-segments for a detailed review and a deeper understanding of the industry.The factors leading to market growth have been listed.
The data has been collected from primary and secondary sources and analyzed by professionals in the field.The study analyses the latest trends and company profiles of the major players in the market.List of leading players:There are various players operating in the market.
